Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis

Area of Science:

• Neuroscience
• Vascular Biology
• Immunology

Background:

• Angiogenesis, or new blood vessel formation, occurs in Multiple Sclerosis (MS) lesions, driven by Vascular Endothelial Growth Factor (VEGF) and other angiogenic molecules.
• This angiogenic response is linked to increased energy demands in inflamed brain tissue and damaged neural cells.
• Similar vascular changes, including blood-brain barrier disruption, are observed in experimental allergic encephalomyelitis (EAE), an MS model.

Purpose of the Study:

• To explore the role of angiogenesis in MS pathogenesis and neuroregeneration.
• To investigate the dual role of VEGF in early inflammation and later neuroprotection.
• To understand the interplay between angiogenesis, neurogenesis, and oligodendrocyte precursor cell maturation in MS.

Main Methods:

• Review of existing literature on angiogenesis in MS and EAE models.
• Analysis of the molecular mechanisms involving VEGF in demyelinating lesions.
• Examination of the neurovascular niche interactions in MS.

Main Results:

• VEGF promotes angiogenesis in MS but its reduced late-phase function hinders neuroregeneration.
• Angiogenesis, neurogenesis, and OPC maturation are interconnected in specific brain regions affected by MS.
• Angiogenesis becomes ineffective in chronic MS due to counteracting vasoconstrictive factors.

Conclusions:

• Therapeutic promotion of angiogenesis is suggested to combat the degenerative phase of MS.
• Targeting angiogenesis could enhance trophic factor supply to the central nervous system.
• Understanding the complex role of angiogenesis is vital for developing effective MS treatments.